Chronic inflammation is a non-traditional risk factor for cardiovascular mortality in the chronic kidney disease (CKD) population. In recent years, the gastrointestinal tract has emerged as a major instigator of systemic inflammation in CKD. Postmortem studies previously discovered gut wall inflammation throughout the digestive tract in chronic dialysis patients. In CKD animals, colon wall inflammation is associated with breakdown of the epithelial tight junction barrier (‘leaky gut') and translocation of bacterial DNA and endotoxin into the bloodstream. Gut bacterial DNA and endotoxin have also been detected in the serum from CKD and dialysis patients, whereby endotoxin levels increase with the CKD stage and correlate with the severity of systemic inflammation in the dialysis population. The CKD diet that is low in plant fiber and symbiotic organisms (in adherence with low potassium, low phosphorus intake) can alter the normal gut microbiome, leading to overgrowth of bacteria that produce uremic toxins such as cresyl and indoxyl molecules. The translocation of these toxins from the ‘leaky gut' into the bloodstream further promotes systemic inflammation, adverse cardiovascular outcomes and CKD progression. Data are lacking on optimal fiber and yogurt consumption in CKD that would favor growth of a more symbiotic microbiome while avoiding potassium and phosphorus overload. Prebiotic and probiotic formulations have shown promise in small clinical trials, in terms of lowering serum levels of uremic toxins and improving quality of life. The evidence points to a strong relationship between intestinal inflammation and adverse outcomes in CKD, and more trials investigating gut-targeted therapeutics are needed.

Keywords:
Gut inflammation, CKD, Tight junction barrier, Microbiome, Uremic toxins, Chronic inflammation
1.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al: Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-352.
2.
Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003;42:864-881.
3.
Kendrick J, Chonchol MB: Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008;4:672-681.
4.
Lau WL, Ix JH: Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism. Semin Nephrol 2013;33:93-105.
5.
Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009;4(suppl 1):S49-S55.
6.
Vaziri ND: Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013;61:992-1000.
7.
Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease - what have we learned in 10 years? Semin Dial 2010;23:498-509.
8.
Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S: Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton) 2012;17:733-738.
9.
Shi K, Wang F, Jiang H, et al: Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014;59:2109-2117.
10.
Feroze U, Kalantar-Zadeh K, Sterling KA, et al: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012;22:317-326.
11.
Szeto CC, Kwan BC, Chow KM, et al: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3:431-436.
12.
McIntyre CW, Harrison LE, Eldehni MT, et al: Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:133-141.
13.
Anders HJ, Andersen K, Stecher B: The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 2013;83:1010-1016.
14.
Ramezani A, Raj DS: The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014;25:657-670.
15.
Hooper LV, Littman DR, Macpherson AJ: Interactions between the microbiota and the immune system. Science 2012;336:1268-1273.
16.
Kranich J, Maslowski KM, Mackay CR: Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol 2011;23:139-145.
17.
Macpherson AJ, Harris NL: Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004;4:478-485.
18.
Qin J, Li R, Raes J, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
19.
Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG Jr, Schaedler RW, Gordon SJ: Bacterial populations of the small intestine in uremia. Nephron 1978;22:63-68.
20.
Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, Schaedler RW: Amine metabolism and the small bowel in uraemia. Lancet 1976;2:818-821.
21.
Vaziri ND, Wong J, Pahl M, et al: Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013;83:308-315.
22.
Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND: Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014;39:230-237.
23.
Meinardi S, Jin KB, Barletta B, Blake DR, Vaziri ND: Exhaled breath and fecal volatile organic biomarkers of chronic kidney disease. Biochim Biophys Acta 2013;1830:2531-2537.
24.
Lee HJ, Pahl MV, Vaziri ND, Blake DR: Effect of hemodialysis and diet on the exhaled breath methanol concentration in patients with ESRD. J Ren Nutr 2012;22:357-364.
25.
Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;114:S12-S19.
26.
Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003;63:1671-1680.
27.
Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007;22:592-596.
28.
Rossi M, Campbell KL, Johnson DW, et al: Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Arch Med Res 2014;45:309-317.
29.
Moradi H, Sica DA, Kalantar-Zadeh K: Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013;38:136-148.
30.
Miyazaki T, Ise M, Hirata M, et al: Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl 1997;63:S211-S214.
31.
Tang WH, Wang Z, Kennedy DJ, et al: Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015;116:448-455.
32.
Lathrop SK, Bloom SM, Rao SM, et al: Peripheral education of the immune system by colonic commensal microbiota. Nature 2011;478:250-254.
33.
Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK: Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985;80:608-611.
34.
Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron 1990;56:306-311.
35.
Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991;32:754-759.
36.
Laukoetter MG, Bruewer M, Nusrat A: Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol 2006;22:85-89.
37.
Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS: Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012;27:2686-2693.
38.
Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S: Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013;38:99-103.
39.
Wang F, Zhang P, Jiang H, Cheng S: Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci 2012;57:2856-2862.
40.
Vaziri ND, Goshtasbi N, Yuan J, et al: Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol 2012;36:438-443.
41.
Vaziri ND, Yuan J, Norris K: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013;37:1-6.
42.
Nusrat A, Turner JR, Madara JL: Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000;279:G851-G857.
43.
Al-Sadi R, Boivin M, Ma T: Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed) 2009;14:2765-2778.
44.
Lau WL, Liu SM, Pahlevan S, et al: Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption. Dig Dis Sci 2014, Epub ahead of print.
45.
Kalantar-Zadeh K, Tortorici AR, Chen JL, et al: Dietary restrictions in dialysis patients: is there anything left to eat? Semin Dial 2015;28:159-168.
46.
Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S: Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol 2013;37:518-525.
47.
Akizawa T, Asano Y, Morita S, et al: Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-467.
48.
Schulman G, Berl T, Beck GJ, et al: Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol 2014;pii:ASN.2014010042.
49.
Vaziri ND, Liu SM, Lau WL, et al: High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014;9:e114881.
50.
Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010;25:219-224.
51.
Chiavaroli L, Mirrahimi A, Sievenpiper JL, Jenkins DJ, Darling PB: Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014, Epub ahead of print.
52.
Simenhoff ML, Dunn SR, Zollner GP, et al: Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996;22:92-96.
53.
Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-355.
54.
Ranganathan N, Ranganathan P, Friedman EA, et al: Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010;27:634-647.
55.
Nakabayashi I, Nakamura M, Kawakami K, et al: Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011;26:1094-1098.
56.
Rossi M, Johnson DW, Morrison M, et al: Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol 2014;15:106.
57.
Arumugam M, Raes J, Pelletier E, et al: Enterotypes of the human gut microbiome. Nature 2011;473:174-180.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.